Advancing Selection of Next-Generation Oral Small Molecule PTH1R Agonist for Clinical Development Initiating Phase 1 Trial for SEP-631, MRGPRX2 NAM Program, for Mast Cell Diseases Updated Cash Runway ...

Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Novo Nordisk wasn ...

Current health news includes a push for board overhaul at Avantor by Engine Capital, Ab&B Bio-Tech's share surge during its ...

We imagine something different, a 100 percent online system that's accessible, personalized, and designed around how people ...

Leaders at Eli Lilly believe heavy investment in the company's manufacturing footprint “sets a high standard that newcomers ...

Novo Nordisk A/S (NYSE:NVO) is among the. Novo Nordisk A/S (NYSE:NVO) lowered its operating profit growth projections to 10–16% (from 16-24%) and revenue growth projections to 8-14% (from 13-21%) at ...

We read with interest the Correspondence by Zhiqi Yao and colleagues1 published in The Lancet Diabetes & Endocrinology, which ...

Shares of WW International Inc., the company known as WeightWatchers, reversed their early gains Monday despite better-than-expected second-quarter revenue amid robust demand for GLP-1 obesity ...

Cornell University researchers have developed an implant system that can treat Type 1 diabetes by supplying extra oxygen to densely packed insulin-secreting cells, without the need for ...

If you’re pregnant or hoping to become pregnant, it’s natural to have questions about your medications. And if you’re taking ...

Novo Nordisk's FY 2025 guidance cuts are driven by softer U.S. Wegovy/Ozempic and GLP-1 trends. Click here to find out why I ...

Novo Nordisk A/S is suffering from headwinds in its core anti-obesity medications market. Click here to find out why NVO ...